Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a report released on Monday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Up 8.3 %

NASDAQ:LPCN opened at $3.07 on Monday. The company has a market capitalization of $16.40 million, a PE ratio of -4.03 and a beta of 1.51. The stock’s 50 day moving average price is $3.39 and its 200 day moving average price is $4.41. Lipocine has a 52-week low of $2.75 and a 52-week high of $11.79.

Hedge Funds Weigh In On Lipocine

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC raised its position in Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 57,464 shares of the specialty pharmaceutical company’s stock after buying an additional 3,248 shares during the quarter. Geode Capital Management LLC owned about 1.07% of Lipocine worth $280,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.